We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

70 hedge funds and large institutions have $19.8M invested in Carisma Therapeutics in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 24 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more capital invested

Capital invested by funds: $11M → $19.8M (+$8.8M)

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

3% more funds holding

Funds holding: 68 → 70 (+2)

4% more call options, than puts

Call options by funds: $1.14M | Put options by funds: $1.09M

0.16% more ownership

Funds ownership: 0.64% → 0.8% (+0.16%)

67% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 24

Holders
70
Holders Change
+2
Holders Change %
+2.94%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
8
Reduced
24
Closed
11
Calls
$1.14M
Puts
$1.09M
Net Calls
+$46K
Net Calls Change
-$10K

Top Buyers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$244K
2
Jane Street
Jane Street
New York
+$150K
3
BWA
Blodgett Wealth Advisors
California
+$143K
4
E
Ergoteles
New York
+$54.7K
5
CL
CSS LLC
Illinois
+$50.2K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$831K
2
BCM
Bridgeway Capital Management
Texas
-$106K
3
Millennium Management
Millennium Management
New York
-$94.3K
4
Morgan Stanley
Morgan Stanley
New York
-$83.7K
5
GCP
GSA Capital Partners
United Kingdom
-$80K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$6.62M +$2.23K +212 +0%
BCM
2
BML Capital Management
Indiana
$5.01M +$4.32M +411,398 New
BlackRock
3
BlackRock
New York
$1.61M -$831K -79,097 -38%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$1.4M +$5.84K +556 +0.5%
Millennium Management
5
Millennium Management
New York
$631K -$94.3K -8,982 -15%
Renaissance Technologies
6
Renaissance Technologies
New York
$621K -$19.3K -1,842 -3%
State Street
7
State Street
Massachusetts
$407K – – –
BWA
8
Blodgett Wealth Advisors
California
$366K +$143K +13,605 +83%
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$361K +$244K +23,196 +359%
Morgan Stanley
10
Morgan Stanley
New York
$341K -$83.7K -7,970 -22%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$287K -$2.87K -273 -1%
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$265K +$13.3K +1,266 +6%
SWP
13
Stratos Wealth Partners
Ohio
$252K -$74 -7 -0%
Group One Trading
14
Group One Trading
Illinois
$211K -$36.3K -3,452 -17%
Northern Trust
15
Northern Trust
Illinois
$200K -$2.26K -215 -1%
Jane Street
16
Jane Street
New York
$174K +$150K +14,250 New
CL
17
CSS LLC
Illinois
$159K +$50.2K +4,781 +58%
Connor, Clark & Lunn Investment Management (CC&L)
18
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$96K +$7.74K +737 +10%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$74.5K – – –
E
20
Ergoteles
New York
$63.5K +$54.7K +5,209 New
Cambridge Investment Research Advisors
21
Cambridge Investment Research Advisors
Iowa
$58K -$21.1K -2,005 -30%
TSS
22
Two Sigma Securities
New York
$51K +$43.9K +4,185 New
AWS
23
AJ Wealth Strategies
New York
$48K -$1.1K -105 -3%
Parallax Volatility Advisers
24
Parallax Volatility Advisers
California
$44.1K – – –
Charles Schwab
25
Charles Schwab
California
$41.4K – – –
1
2 3 4

CARM Hedge Fund Activity: Q4 2022 in Review

70 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2022, worth a combined $19.8M — up 80% from $11M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CARM positions and 11 closed out — a net gain of 2 holders — while 8 added to existing stakes and 24 trimmed.

The largest buyer was Acadian Asset Management, adding an estimated $244K. The largest seller was BlackRock, cutting an estimated $831K.

  • 70 institutional investors held Carisma Therapeutics (CARM) as of Q4 2022, up from 68 in Q3 2022.
  • Funds reported $19.8M of Carisma Therapeutics stock for Q4 2022, up 80% quarter-over-quarter.
  • 13 funds opened new Carisma Therapeutics positions in Q4 2022 and 11 closed out, a net change of +2 holders.
  • The largest Carisma Therapeutics buyer in Q4 2022 was Acadian Asset Management, an estimated $244K added.
  • The largest Carisma Therapeutics seller in Q4 2022 was BlackRock, an estimated $831K sold.

Based on aggregated 13F filings for Q4 2022.